CTRI/2016/06/007006已完成4 期
A Double Blind, placebo controlled, Clinical study to evaluate the efficacy and safety of Ashwagandha in stress disorders
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Mild to moderate stress disorders characterized with Difficulty in concentration, Physical exhaustion, Anxiety, restlessness, insomnia, Headache, fatigue, loss of appetite, Phobia, Sweating, mental confusion etc.
- •Age >18 years, both male and female subjects.
- •Hematologic and Biochemical parameters within normal limits.
排除标准
- •Patients with severe Psychiatric conditions.
- •Pregnant & Breast feeding Women.
- •Patients with severe Hepatic/ cardiac/ mental illness.
- •History of Alcohol or smoking abuse.
- •Patients unwilling to provide informed consent or abide by the requirements of the study
研究者
相似试验
招募中
3 期
Ginger caplets in Post operative nausea and vomitingCTRI/2012/10/003063The Himalaya Drug Company50
已完成
不适用
A study to find the difference in bioavailability of 3 different ingredients through FenuMAT delivery system and its comparison with natural existing forms.CTRI/2018/03/012753Akay Flavours and Aromatics Private Limited45
已完成
不适用
A study to find the increase in bioavailability of 2 different ingredients through FenuMAT delivery system and its comparison with natural existing forms.CTRI/2018/03/012875Akay Flavours and Aromatics Private Limited30
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-ITGENFIT150
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-FRGENFIT150